{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 77/80', 'APPENDIX 4: KNOWN POTENT P-GP INHIBITORS', 'Excluded medication:', 'Amiodarone', 'Azelastine', 'Azithromycin - Clarithromycin - Erythromycin - Roxithromycin - Telithromycin', '(unless used under the condition described in Section 4.5.3.2)', 'Cyclosporine', 'Itraconazole - Ketoconazole', 'Tamoxifen', 'Verapamil', 'This list is intended as a guidance for the investigator.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 78/80', 'APPENDIX 5: MEDICATION KNOWN TO PROLONG QT', 'INTERVAL', 'This is based on the CredibleMeds list of medication known to prolong QT interval/cause', 'Torsade de Pointes (Woosley RL. et al., 2018).', 'Medication to be used with caution:', 'Disopyramide', 'Dofetilide', 'Flecainide', 'Ibutilide', 'Quinidine', 'Sotalol', 'Hydroxychloroquine', 'This list is intended as a guidance for the investigator.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 79/80', 'SIGNATURE PAGE - SPONSOR', 'Study Title:', 'A Phase 2a randomized, double-blind, placebo-controlled, multi-center study', 'to evaluate the efficacy, safety, and tolerability of orally administered', 'GLPG1690 for 24 weeks in subjects with systemic sclerosis', 'CSP Version:', '5.00', 'Date:', '28-Apr-2020', 'This clinical study protocol has been reviewed and approved by the sponsor to ensure', 'compliance with International Council for Harmonisation of Technical Requirements for', 'Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practices (GCP) and', 'applicable regulatory requirements.', 'An electronic signature for the sponsor is provided at the end of the document.', 'MD', 'Study Physician', 'Signature', 'Date', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}